Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Alector total Funding
Alector latest funding size
Time since last funding
|a month ago|
|Lilly Asia Ventures, Federated Kaufmann Fund, Topspin Partners, Deerfield Management, New Leaf Venture Partners, Dementia Society, MRL Ventures, OrbiMed, OrbiMed Advisors, Casdin Capital, GV, Polaris Partners, Amgen Ventures, Perceptive Advisors, Section 32, AbbVie Ventures, Foresite Capital, the Dementia Discovery Fund, Euclidean Capital, Mission Bay Capital|